Voyager Therapeutics
VYGR · Nasdaq · United States
Share price · VYGR
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VYGR's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026+9.9%
- 10 Nov 2026-8.3%
- Day beforeEarnings date (period ending 2026-09-30)
- 22 Oct 2026-7.9%
- 21 Oct 2026-7.8%
- 19 Oct 2026+7.9%
Nothing announced by VYGR that day or the session before.
- 14 Oct 2026-6.5%
Nothing announced by VYGR that day or the session before.
- 12 Oct 2026-7.3%
Nothing announced by VYGR that day or the session before.
- 2 Oct 2026-8.4%
Nothing announced by VYGR that day or the session before.
- 23 Sep 2026-8.6%
Nothing announced by VYGR that day or the session before.
- 17 Mar 2026-9.3%
Nothing announced by VYGR that day or the session before.
Share of unusual movement by asset
For each asset, the share of VYGR's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 20% |
| Sessions with no dated event | — | 80% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | Tau (monoclonal antibody)Monoclonal antibody | Alzheimer's Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $4.0M | $24M | $51M+ $58M short-term inv. | $25M-$20M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $3.2M | $22M | $39M+ $81M short-term inv. | $24M-$26M operating cash flow | report ↗ |
| 2026-Q1 | $2.6M | $25M | $46M+ $98M short-term inv. | $28M-$33M operating cash flow | report ↗ |
| 2025-Q3 | $13M | $36M | $51M+ $164M short-term inv. | $28M-$31M operating cash flow | report ↗ |
| 2025-Q2 | $5.2M | $31M | $47M+ $172M short-term inv. | $33M-$33M operating cash flow | report ↗ |
| 2025-Q1 | $6.5M | $32M | $78M+ $161M short-term inv. | $31M-$38M operating cash flow | report ↗ |
| 2024-Q3 | $25M | $30M | $115M+ $233M short-term inv. | $9.0M-$28M operating cash flow | report ↗ |
| 2024-Q2 | $30M | $34M | $79M+ $295M short-term inv. | $10M-$32M operating cash flow | report ↗ |
| 2024-Q1 | $20M | $27M | $146M+ $256M short-term inv. | $11M$59M operating cash flow | report ↗ |
| 2023-Q3 | $4.6M | $26M | $67M+ $188M short-term inv. | $26M-$21M operating cash flow | report ↗ |
| 2023-Q2 | $4.8M | $22M | $246M+ $28M short-term inv. | $22M-$0.8M operating cash flow | report ↗ |
| 2023-Q1 | $150M | $19M | $270M+ $5.0M short-term inv. | —$124M operating cash flow | report ↗ |
| 2022-Q3 | $41M | $19M | $98M+ $35M short-term inv. | —-$16M operating cash flow | report ↗ |
| 2022-Q2 | $0.7M | $13M | $80M+ $70M short-term inv. | $19M-$18M operating cash flow | report ↗ |
| 2022-Q1 | $0.7M | $14M | $134M+ $35M short-term inv. | $21M$34M operating cash flow | report ↗ |
| 2021-Q3 | $1.5M | $18M | $113M+ $10M short-term inv. | $25M-$21M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $40M | $135M | $68M+ $131M short-term inv. | $30M-$132M operating cash flow | report ↗ |
Voyager Therapeutics reported full-year 2025 collaboration revenue of $40.4M, down 49.5% YoY from $80.0M, while R&D spend was $134.7M, up 5.7% YoY from $127.4M. The company ended 2025 with a cash position of $201.7M in cash, cash equivalents, and marketable securities, and reported a net loss of $119.7M versus $65.0M in the prior year. No analyst consensus comparison was provided in the materials.
For 2026, Voyager expects its cash runway to extend into 2028, with potential additional non-dilutive milestone payments of up to $2.4B. Pipeline expectations include VY1706 IND submission in Q2 2026 and first-in-human dosing in H2 2026, tau PET imaging data from the VY7523 MAD trial in H2 2026, and Neurocrine’s planned initiation of a clinical trial for NBIB-223 in Friedreich’s ataxia in H2 2026 pending FDA clearance. The company also highlighted a Voyager NeuroShuttle proof-of-concept study supporting sustained brain exposure and noted that its APOE gene therapy program was paused to prioritize more advanced programs.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $80M | $127M | $74M+ $195M short-term inv. | $16M-$15M operating cash flow | report ↗ |
| 2023-FY | $250M | $92M | $70M+ $162M short-term inv. | —$78M operating cash flow | report ↗ |
| 2022-FY | $41M | $61M | $100M+ $20M short-term inv. | $12M-$13M operating cash flow | report ↗ |
| 2021-FY | $37M | $74M | $119M+ $15M short-term inv. | $18M-$54M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 11 sales ($298K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-01 | Swartz Robin · President | Award / grant | 68,250 | — | — | Form 4 |
| 2026-11-01 | Carter Todd Alfred · Chief Scientific Officer | Award / grant | 33,000 | — | — | Form 4 |
| 2026-11-01 | Swartz Robin · President | Award / grant (derivative) | 318,500 | — | — | Form 4 |
| 2026-11-01 | Carter Todd Alfred · Chief Scientific Officer | Award / grant (derivative) | 154,000 | — | — | Form 4 |
| 2026-06-09 | PIERCE GLENN · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-09 | Colon Grace · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-09 | GERAGHTY JAMES A · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
| 2026-06-09 | Onyia Jude · director | Award / grant (derivative) | 30,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 134 reporting institutions held 33.5M shares ($127.5M, 53.9% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 5,568,381 | $21.5M |
| 2 | ARMISTICE CAPITAL, LLC | 3,500,000 | $13.5M |
| 3 | MILLENNIUM MANAGEMENT LLC | 3,428,571 | $13.2M |
| 4 | Vestal Point Capital, LP | 3,002,936 | $11.6M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 2,283,253 | $8.8M |
| 6 | Opaleye Management Inc. | 1,150,000 | $4.4M |
| 7 | Erste Asset Management GmbH | 1,095,141 | $4.2M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 1,049,978 | $4.1M |
| 9 | STATE STREET CORP | 948,226 | $3.7M |
| 10 | DIMENSIONAL FUND ADVISORS LP | 875,568 | $3.4M |
| 11 | VANGUARD PORTFOLIO MANAGEMENT LLC | 725,769 | $2.8M |
| 12 | MORGAN STANLEY | 681,711 | $2.6M |
| 13 | TWO SIGMA INVESTMENTS, LP | 615,660 | $2.4M |
| 14 | RENAISSANCE TECHNOLOGIES LLC | 578,024 | $2.2M |
| 15 | SPHERA FUNDS MANAGEMENT LTD. | 469,761 | $1.8M |